Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANIRELIX ACETATE vs ANDROID 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART),Off-label: Treatment of hormone-sensitive cancers (e.g., prostate cancer) when rapid suppression of gonadotropins is needed
Testosterone replacement therapy for male hypogonadism,Off-label: delayed puberty in males
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement.
Hepatic via CYP3A4 and CYP2B6; undergoes first-pass metabolism.
Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%).
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein.
98% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding.
Vd approximately 1.0 L/kg; indicates extensive tissue distribution, especially to reproductive organs and bone marrow.
Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection.
Oral: 15–25% due to first-pass metabolism; buccal or transdermal: higher, but not commercially available for this formulation.
No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (Cr Cl < 30 m L/min).
No specific dose adjustment required based on GFR; caution in severe impairment (Cr Cl <30 m L/min) due to potential fluid retention.
No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment.
Contraindicated in Child-Pugh class B and C cirrhosis due to hepatotoxicity risk; in class A, use with caution and monitor liver function.
Not approved for use in pediatric patients.
Not recommended for use in children as it may cause premature epiphyseal closure and virilization; limited data.
Not approved for use in geriatric patients.
Increased risk of prostatic hyperplasia and carcinoma; use lowest effective dose with regular prostate monitoring.
None
Warning: Prolonged use may cause virilization in women, premature epiphyseal closure, and increased risk of prostatic hypertrophy/carcinoma.
Hypersensitivity reactions (urticaria, angioedema) have been reported,Ovarian hyperstimulation syndrome (OHSS) may occur with ART,Congenital abnormalities cannot be excluded; pregnancy should be excluded before use
Monitor liver function, lipid profile, and prostate-specific antigen; risk of edema in patients with cardiac disease; avoid use in patients with sleep apnea.
Hypersensitivity to ganirelix or any component,Known or suspected pregnancy,Lactation (not recommended due to potential neonatal effects)
Known or suspected prostate cancer; breast cancer in males; hypersensitivity to androgens; pregnancy and lactation.
No significant food interactions. Grapefruit may theoretically affect metabolism but data are lacking; caution is advised.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit salt intake to reduce fluid retention. Alcohol may increase risk of liver toxicity.
Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption.
Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial fusion. Risk is highest during first trimester but applies throughout gestation.
Unknown if excreted in human breast milk; M/P ratio not available. Risk of adverse effects in infant due to potential hormonal activity. Use caution; avoid if possible.
Excretion into human milk is unknown. Due to potential for androgenic effects in nursing infants, breastfeeding is not recommended. No M/P ratio available.
No dose adjustments in pregnancy; contraindicated. If inadvertently used, discontinue immediately; no study on pharmacokinetic changes in pregnancy.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist for pregnant patients.
Administer subcutaneously in the abdomen. Rotate injection sites to prevent lipodystrophy. Monitor for ovarian hyperstimulation syndrome (OHSS) especially in patients with polycystic ovary syndrome. Use caution in patients with renal impairment.
Android 5 (methyltestosterone) is an androgenic anabolic steroid used for hypogonadism and delayed puberty. Monitor liver function due to hepatotoxicity. Use with caution in elderly due to increased risk of prostatic hypertrophy and carcinoma. Can cause fluid retention in patients with cardiac, renal, or hepatic disease. Avoid in patients with breast cancer or known or suspected prostate cancer.
Inject exactly as prescribed, typically once daily during the stimulation phase.,Do not skip doses; missed doses may reduce effectiveness.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain immediately.,Store at room temperature (20-25°C) and protect from light.,Use within 30 days after first use.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report any signs of liver problems: yellowing of skin or eyes, dark urine, severe stomach pain.,Women should report any signs of virilization: hoarseness, acne, menstrual changes, growth of facial hair.,Men should report any breast enlargement, changes in urination, or priapism.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Do not use if you are pregnant or planning to become pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANIRELIX ACETATE vs ANDROID 5, answered by our medical review team.
GANIRELIX ACETATE is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. ANDROID 5 is a Androgen that works by Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANIRELIX ACETATE and ANDROID 5 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANIRELIX ACETATE is: 250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.. The standard adult dose of ANDROID 5 is: 2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANIRELIX ACETATE and ANDROID 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANIRELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) . ANDROID 5 is classified as Category C. Pregnancy Category X. ANDROID 5 (oxandrolone) is contraindicated in pregnancy due to teratogenic effects including masculinization of female fetus, clitoral enlargement, and labial. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.